¿¬¼ö°­ÁÂ
(¿Â¶óÀÎ) 2021 ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ*´ëÇÑ°¨¿°ÇÐȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ : 2021-04-02
(¿Â¶óÀÎ) 2021 ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ*´ëÇÑ°¨¿°ÇÐȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ : 2021-04-02
±³À°ÀÏÀÚ : 2021-04-02
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2021 ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ*´ëÇÑ°¨¿°ÇÐȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ      
ÁÖÃÖ±â°ü : ´ëÇÑÇ×±Õ¿ä¹ýÇÐȸ(18.7 ¸íĪº¯°æ ´ëÇÑÈ­Çпä¹ýÇÐȸ)
´ã´çÀÚ : ¹Ú½ÂÀ±
¿¬¶ôó : 02-557-1755  
À̸ÞÀÏ : ksc@ksac.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í Á¤È¸¿ø Àü°øÀÇ 5¸¸¿ø ÀüÀÓÀÇ 8¸¸¿ø Àü¹®ÀÇ ¹× ÀÏ¹Ý 10¸¸¿øºñȸ¿ø Àü°øÀÇ 7¸¸¿ø ÀüÀÓÀÇ 10¸¸¿ø Àü¹®ÀÇ ¹× ÀÏ¹Ý 12¸¸¿ø      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ08:00~08:50 CMV management strategy in allo-HSCT - After LETERMOVIR  À̵¿°Ç(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ09:00~09:25 Treatment strategy: the Korean guideline  ¿°Áؼ·(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ09:25~09:50 Treatment strategy: the Korean experience  ±èÁø¿ë(ÀÎõÀÇ·á¿ø) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ09:50~10:15 Diagnostic strategy: diagnostic tests for COVID-19  È«±âÈ£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ10:15~10:40 Diagnostic strategy: the role of rapid diagnostics  ±è³²Áß(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ10:50~11:25 COVID-19 vaccines  ÃÖ¿ø¼®(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ11:25~12:00 Future of COVID-19 in the post-vaccine era  Á¤ÀçÈÆ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ12:30~13:00 Special Lecture  ±è¹ÎÀÚ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ13:00~13:50 The strategy of rapid initiation with BIKTARVY  ±èÅÂÇü(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ15:20~15:45 Vancomycin vs. metronidazole for clostridium difficile infection  ±èÁöÀº(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ15:45~16:10 Beta-lactam/beta-lactamase inhibitors for ESBL-producing pathogens  ±Ç±âÅÂ(°æºÏÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ16:10~16:35 Combination vs. monotherapy for severe MRSA infections  ¼Û°æÈ£(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04¿ù 02ÀÏ ¿Â¶óÀΠ16:35~17:00 Combination vs. monotherapy for severe carbapenem-resistant GNR infections  °­Ã¶ÀÎ(¼º±Õ°üÀÇ´ë) 
  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] Á¦26Â÷ °¡Å縯ÀÇ´ë ½ÅÀå³»°ú ¿¬¼ö±³À° (Clinical Topics on Hemodialysis Vascular Access) : 2024-03-31

±³À°ÀÏÀÚ : 2024-03-31 ±³À°Àå¼Ò : °¡Å縯ÀÇ´ë ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ ±³À°ÁÖÁ¦ : Á¦26Â÷ °¡Å縯ÀÇ´ë ½ÅÀå³»°ú ¿¬¼ö±³À° (Clinical Topics on Hemodialy

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,381 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ) Á¦4ȸ °­µ¿¼º½Éº´¿ø ¼Ò¾Æû¼Ò³â°ú ¿¬¼ö°­Á "Äڷγª19 ½Ã´ëÀÇ ¼Ò¾Æû¼Ò³â°ú ¸¸¼ºÁúȯ Áø·á ..

(¿Â¶óÀÎ) Á¦4ȸ °­µ¿¼º½Éº´¿ø ¼Ò¾Æû¼Ò³â°ú ¿¬¼ö°­Á "Äڷγª19 ½Ã´ëÀÇ ¼Ò¾Æû¼Ò³â°ú ¸¸¼ºÁúȯ Áø·á ¹× »ó´ã" : 2021-06-26 ±³À°ÀÏÀÚ : 2021-06-26 ±³À°Àå¼Ò : ¿Â

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,721 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024³â Á¦75Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷) : 2024-04-17

±³À°ÀÏÀÚ : 2024-04-17 ±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ ºÎ»ê ±³À°ÁÖÁ¦ : 2024³â Á¦75Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ ´ã´çÀÚ : °­ÈÆ ¿¬¶ôó

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,264 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ) 2023³â ¼ÛÆı¸ÀÇ»çȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ (5¿ù) : 2023-05-20

±³À°ÀÏÀÚ : 2023-05-20 ±³À°Àå¼Ò : ¿Â¶óÀÎ (VOD ´çÀÏ 24½Ã°£ ¼ÛÃâ) ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2023³â ¼ÛÆı¸ÀÇ»çȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ (5¿ù)ÁÖÃÖ±â°ü : ¼­¿ïƯ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 6,808 , ´ñ±Û¼ö : 0

[¼­¿ï] ´ëÇѳ»ºÐºñÇÐȸ SICEM 2024(1ÀÏÂ÷) : 2024-04-11

±³À°ÀÏÀÚ : 2024-04-11 ±³À°Àå¼Ò : ±×·£µå ¿öÄ¿Èú ¼­¿ï ±³À°ÁÖÁ¦ : SICEM 2024(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñÇÐȸ ´ã´çÀÚ : ¹Ú¼öºó ¿¬¶ôó : 02-2038-0

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,282 , ´ñ±Û¼ö : 0